Everything you need to know about TMS vs Spravato (Esketamine): Choosing Between the Two Big Non-Pill Options in 2026 — how it works, what it costs, and how to find a provider who actually knows what they're doing.
The TMS Patient Buyer's Guide
Everything to know before your first consult — questions to ask, what to expect, and how to compare providers.
If your psychiatrist has brought up both TMS and Spravato, it means one thing: the antidepressants you have tried have not done enough. That is its own kind of tiring. You did the responsible thing, gave the pills time to work, dealt with the side effects, and you are still not where you need to be.
Both of these are real, FDA-backed options built for exactly this situation. The harder part is that they work in completely different ways, and picking between them depends less on which one is “better” and more on which one fits your life, your medical history, and your comfort level.
What You’ll Learn
- What TMS and Spravato are, and how their mechanisms differ
- How each is actually delivered, session by session
- The real side-effect profiles
- How fast each one tends to work, and what “durable” means for each
- Cost and insurance differences
- Who tends to choose which
What Each One Actually Is
TMS (transcranial magnetic stimulation) uses a magnetic coil placed against your scalp to deliver pulses that stimulate the parts of your brain involved in mood regulation, most often the left dorsolateral prefrontal cortex. Nothing enters your bloodstream. There is no drug, no systemic exposure. It is a device-based treatment, FDA-cleared for depression since 2008.
Spravato (esketamine) is a nasal spray form of ketamine, FDA-approved in 2019 for treatment-resistant depression, originally alongside an oral antidepressant rather than as a standalone. In 2020 the FDA also approved it for depression with suicidal thoughts or behavior. It is a controlled substance and works through the glutamate system rather than the serotonin and norepinephrine pathways most antidepressants target, which is part of why it can help people who have not responded to standard medications.
Both require documented failure of prior medication before insurance will typically cover them. Neither is experimental.
How Each Is Delivered
TMS is a course, not a single visit. You come in five days a week for roughly six to seven weeks, around 30 to 36 sessions, each running 20 to 40 minutes. You are awake and alert the whole time, and you drive yourself to and from every appointment.
Spravato works differently. You self-administer the nasal spray under supervision in a certified treatment center, then stay for roughly two hours of monitoring afterward. That two-hour window is an FDA REMS (Risk Evaluation and Mitigation Strategy) requirement, not optional. You cannot drive yourself home the day of treatment — you need a ride every session. Dosing typically starts twice a week for the first month, then tapers to weekly or every other week.
If your job cannot absorb two-plus hours of downtime and a ride requirement multiple times a week, that gap matters as much as anything else here.
Side Effects: Two Different Profiles
TMS side effects are mostly local: scalp discomfort during sessions, especially early on, and a headache afterward that usually responds to over-the-counter pain relief. Seizure is a listed risk but rare, and clinics screen for it beforehand. No dissociation, no sedation, no next-day hangover.
Spravato side effects are more involved. Dissociation is expected — a sense of detachment from your body or surroundings that typically resolves within the monitoring window. Sedation and drowsiness are common. Blood pressure rises during and shortly after dosing, part of what the clinic is watching for, and it can be a problem if you have uncontrolled hypertension. Nausea shows up for some people. Because esketamine is a Schedule III controlled substance with real abuse potential, it comes with the REMS oversight and must be administered in a certified setting — you never take it home.
Neither profile is inherently worse. They are just different kinds of hard to live with.
Speed of Response
Esketamine can act fast — some people notice a shift within days, part of why it earned a specific approval for depression with suicidal ideation, where speed matters clinically. TMS builds more gradually, with most responders noticing change over the first two to four weeks of the course. If timeline urgency is a major factor for you, say so directly to your psychiatrist rather than assuming.
Durability and Maintenance
There is no strong body of direct head-to-head research comparing how long each treatment’s effects last, so we will not pretend there is. What we do know from how each is used clinically: TMS is delivered as a defined course, and many responders stay well for months afterward, sometimes needing a maintenance session or repeat course later. Spravato is built around ongoing maintenance from the start — after induction, dosing typically continues on a taper, often indefinitely, because esketamine’s effects are not expected to persist the way a completed TMS course’s can. That is a structural difference in how the two are designed to be used, not just a footnote.
Insurance and Cost
Both are more likely to be covered than a few years ago, but it still depends on your plan. TMS coverage generally requires documented failure of two or more antidepressant trials plus prior authorization; once approved, many insurers cover the bulk of a defined course. Spravato coverage similarly requires documentation of treatment resistance, but because dosing often continues indefinitely, you are budgeting for an ongoing treatment rather than a finite one — copays can add up over a year of maintenance dosing in a way a completed TMS course does not.
Call your insurer and ask about each separately. The requirements are rarely identical, even under the same policy.
Who Tends to Choose Which
Toward TMS: can’t arrange a ride multiple times a week or take two-plus hours off per session, want to keep working and driving normally on treatment days, uncomfortable with dissociative effects even supervised ones, a personal or family history that makes a controlled substance a harder conversation, or uncontrolled blood pressure that rules out esketamine’s cardiovascular effects.
Toward Spravato: need faster relief, particularly if suicidal ideation makes speed clinically urgent, have a metal implant or seizure history that rules out TMS, have reliable transportation support for the monitoring requirement, or can manage twice-weekly visits that taper down but not daily weekday visits for six-plus weeks.
Medical exclusions run both directions. TMS is generally not appropriate with certain metal implants or a seizure history. Spravato is not appropriate with uncontrolled hypertension, certain cardiovascular or aneurysm risks, or a history that makes a controlled substance clinically unwise. Your psychiatrist screens for both before recommending either.
They Are Not Mutually Exclusive
Choosing one now does not close the door on the other. Some people try TMS first because of the logistics and side-effect profile, then move to Spravato if response is incomplete. Others start with Spravato for faster relief and add TMS later for a more durable structural change. Some clinics are even combining the two directly, using ketamine’s window of enhanced neuroplasticity to potentially make TMS sessions more effective — we cover that mechanism, protocol, and cost breakdown in TMS and Ketamine Together.
If you are still weighing either of these against standard antidepressants, TMS vs. Medication walks through that decision in the same head-to-head format. And if “treatment-resistant depression” is a term you are still working out, TMS for Treatment-Resistant Depression explains what it actually means and how it’s diagnosed.
Talk to a Psychiatrist Before Deciding
Nothing here replaces an actual evaluation. Your treatment history, current medications, medical conditions, and personal preferences all factor into what your psychiatrist recommends first, if not both in sequence. Bring your full medication history to that conversation — what you tried, for how long, and what happened.
If you are not sure whether you would even qualify for TMS, our TMS candidacy checklist is a fast way to see where you stand before booking an evaluation.
Key Takeaways
- TMS uses magnetic pulses with no systemic drug exposure. Spravato is an FDA-approved intranasal esketamine, a controlled substance typically used alongside an oral antidepressant.
- TMS means daily weekday visits for six to seven weeks, but you drive yourself home each time. Spravato means fewer visits, but each one requires two hours of supervised monitoring and a ride home.
- TMS side effects are mostly scalp discomfort and headache. Spravato side effects include dissociation, sedation, and a temporary rise in blood pressure.
- Esketamine can act within days. TMS builds gradually over weeks.
- Both usually require documented failure of prior antidepressants for coverage, but Spravato is typically structured as ongoing maintenance dosing rather than a finite course.
- They are not mutually exclusive. Some patients try one, then the other, or combine them under specialist supervision.
Frequently Asked Questions
Is TMS or Spravato better for treatment-resistant depression?
There is no definitive head-to-head trial declaring one superior. Both are FDA-backed options for treatment-resistant depression, working through different mechanisms. The right choice usually comes down to your medical history, how fast you need relief, your comfort with each side-effect profile, and practical factors like transportation and time commitment. Talk to a psychiatrist about your specific case.
Can I drive myself home after Spravato treatment?
No. Spravato requires roughly two hours of in-office monitoring after dosing under an FDA REMS program, and you cannot drive yourself home that day. You need to arrange a ride each session. TMS has no such restriction — you can drive yourself to and from every appointment.
Which works faster, TMS or Spravato?
Esketamine can produce a mood shift within days for some people, part of why it has a specific approval for depression with suicidal ideation. TMS tends to build more gradually, with most responders noticing change over the first two to four weeks of the course.
Does insurance cover Spravato and TMS the same way?
Not exactly. Both typically require documentation of treatment-resistant depression and prior authorization, but TMS is usually covered as a defined course, while Spravato coverage extends into ongoing maintenance dosing since treatment often continues indefinitely. Call your insurer and ask about each separately.
Can I do TMS and Spravato together?
Some clinics do combine ketamine-based treatments with TMS, using the neuroplasticity window ketamine opens to potentially make TMS sessions more effective. This is not a first-line approach and should be done under specialist supervision. See our guide on TMS and ketamine together for how that combination protocol typically works.
Ready to Explore Your TMS Options?
Browse verified TMS providers, read real reviews, and find the right treatment for your situation.
